181 related articles for article (PubMed ID: 21888857)
1. Clinical significance of FGF-23 measurement in dialysis patients.
Jongbloed F; Galassi A; Cozzolino M; Zietse R; Chiarelli G; Cusi D; Brancaccio D; Gallieni M
Clin Nephrol; 2011 Sep; 76(3):201-9. PubMed ID: 21888857
[TBL] [Abstract][Full Text] [Related]
2. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
[TBL] [Abstract][Full Text] [Related]
3. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
4. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
5. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
[TBL] [Abstract][Full Text] [Related]
6. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.
Wesseling-Perry K; Pereira RC; Wang H; Elashoff RM; Sahney S; Gales B; Jüppner H; Salusky IB
J Clin Endocrinol Metab; 2009 Feb; 94(2):511-7. PubMed ID: 19050056
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
[TBL] [Abstract][Full Text] [Related]
9. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
Nakano C; Hamano T; Fujii N; Obi Y; Matsui I; Tomida K; Mikami S; Inoue K; Shimomura A; Nagasawa Y; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
Bone; 2012 Jun; 50(6):1266-74. PubMed ID: 22425694
[TBL] [Abstract][Full Text] [Related]
10. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
[TBL] [Abstract][Full Text] [Related]
11. FGF-23 in patients with end-stage renal disease on hemodialysis.
Imanishi Y; Inaba M; Nakatsuka K; Nagasue K; Okuno S; Yoshihara A; Miura M; Miyauchi A; Kobayashi K; Miki T; Shoji T; Ishimura E; Nishizawa Y
Kidney Int; 2004 May; 65(5):1943-6. PubMed ID: 15086938
[TBL] [Abstract][Full Text] [Related]
12. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Shigematsu T; Kazama JJ; Yamashita T; Fukumoto S; Hosoya T; Gejyo F; Fukagawa M
Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
14. Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23.
Mazzaferro S; Pasquali M; Pugliese F; Citterio F; Gargiulo A; Rotondi S; Tartaglione L; Conte C; Pirrò G; Taggi F
J Nephrol; 2012; 25(6):1108-18. PubMed ID: 22383345
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
[TBL] [Abstract][Full Text] [Related]
16. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
[TBL] [Abstract][Full Text] [Related]
17. Circadian variation of mineral and bone parameters in end-stage renal disease.
Trivedi H; Szabo A; Zhao S; Cantor T; Raff H
J Nephrol; 2015 Jun; 28(3):351-9. PubMed ID: 25138650
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients.
Hryszko T; Rydzewska-Rosolowska A; Brzosko S; Koc-Zorawska E; Mysliwiec M
Ther Apher Dial; 2012 Apr; 16(2):146-51. PubMed ID: 22458393
[TBL] [Abstract][Full Text] [Related]
19. Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients.
Seiler S; Lucisano G; Ege P; Fell LH; Rogacev KS; Lerner-Gräber A; Klingele M; Ziegler M; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2013 Oct; 8(10):1764-72. PubMed ID: 23846463
[TBL] [Abstract][Full Text] [Related]
20. Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients.
Doi Y; Hamano T; Ichimaru N; Tomida K; Obi Y; Fujii N; Yamaguchi S; Oka T; Sakaguchi Y; Matsui I; Kaimori JY; Abe T; Imamura R; Takahara S; Tsubakihara Y; Nonomura N; Isaka Y
Sci Rep; 2020 Aug; 10(1):13766. PubMed ID: 32792668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
